A decade ago, the US Supreme Court decided Association for Molecular Pathology v.
Myriad Genetics, Inc., concluding that isolated genes were not patentable subject matter …

The sufficiency of disclosure of medical artificial intelligence patents | Nature Biotechnology
Skip to main content Thank you for visiting nature.com. You are using a browser version with …

Recent technical breakthroughs underscore the potential of second generation (2G)
quantum technologies including quantum simulation, quantum sensing and metrology …

Mapping the patent landscape of medical machine learning | Nature Biotechnology Skip to main
content Thank you for visiting nature.com. You are using a browser version with limited support …

How does emerging patent case law in the US and Europe affect precision medicine? | Nature
Biotechnology Skip to main content Thank you for visiting nature.com. You are using a browser …

European patent protection for medical uses of known products and drug repurposing | Nature
Biotechnology Skip to main content Thank you for visiting nature.com. You are using a browser …

Over its 30 or so years of existence, the genomic commons—the worldwide collection of
publicly accessible repositories of human and nonhuman genomic data—has enjoyed …

This review explores the recent divergence in international patent law relating to genes and
associated subject matter. This divergence stems primarily from decisions of the highest …

Mapping the European patent landscape for medical uses of known products | Nature
Biotechnology Skip to main content Thank you for visiting nature.com. You are using a browser …

After Myriad, what makes a gene patent claim 'markedly different' from nature? | Nature
Biotechnology Skip to main content Thank you for visiting nature.com. You are using a browser …